Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, Chief Scientific Officer | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,733 |
Reported balance
After 2026-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 39,200 · Balance 137,733 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.78 · Expires 2036-02-29 | Direct | 56,000 |
Reported balance
After 2026-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-01 · Grant · Acquired 56,000 · Balance 56,000 F2: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 16:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001193125-26-088251 · ownership.xml · derivative · entry 2 Schultes Birgit C · CIK 0002051419 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 39,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088251 · ownership.xml · nonDerivative · entry 1 Schultes Birgit C · CIK 0002051419 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,733 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 16:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,508 | $9.21 | $78,358.68 |
DisclosureSEC source: 0001193125-26-006292 · ownership.xml · nonDerivative · entry 1 Schultes Birgit C · CIK 0002051419 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,533 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. F2 · balance_after: Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 17:13 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 31 | $17.38 | $538.78 |
DisclosureSEC source: 0001193125-25-230424 · ownership.xml · nonDerivative · entry 1 Schultes Birgit C · CIK 0002051419 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,184 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 53,714 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-25-032101 · ownership.xml · derivative · entry 2 Schultes Birgit C · CIK 0002051419 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,714 Underlying: Common Stock · 53,714 shares Expires 2035-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 37,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032101 · ownership.xml · nonDerivative · entry 1 Schultes Birgit C · CIK 0002051419 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,215 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.